Guess which ASX 300 stock is jumping amid huge profit growth

The company is forecasting its profits to more than double in the first half.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Nanosonics Ltd (ASX: NAN) shares are having a strong session on Thursday.

In early trade, the ASX 300 stock is up 6% to $3.97.

A young woman with her mouth open and her hands out showing surprise and delight.

Image source: Getty Images

Why is this ASX 300 stock is jumping?

Investors have been buying the infection prevention company's shares this morning following the release of a half-year update.

According to the release, Nanosonics is expecting to report a sizeable increase in revenue and profits for the half after returning to form in FY 2025.

For the six months ended 31 December, the ASX 300 stock expects total revenue to be approximately $93.6 million. This is up 18% from $79.6 million in the prior corresponding period. It is also up 4% from the $90.4 million recorded in the second half of FY 2024.

Commenting on its top line performance during the half, the company's CEO and president, Michael Kavanagh, said:

The expected first half revenue result of $93.6m represents a good start to the year up 18% compared to pcp and 4% compared to H2 FY24. Revenue growth was primarily driven by 20% growth (compared to pcp) in our consumables and service annuity revenue streams. The total number of trophon units sold in the first half was broadly in line with internal forecasts and was similar to the total number sold in the pcp, with overall capital revenue up 11% compared to pcp.

Strong profit growth

The company's gross margin for the half is expected to be approximately 78.5%. This is down from 79.7% in the prior corresponding period but up from 76.3% in the second half of FY 2024.

Nanosonics' operating expenses are expected to be approximately $66.7 million for the half. This is up 10% from the prior corresponding period and 3% on the previous half.

Nevertheless, this couldn't stop the ASX 300 stock from delivering strong profit growth. Management expects a profit before tax of approximately $10.9 million for the six months. This is more than double the $4.9 million recorded in the prior corresponding period and is up from $8.1 million in second half of FY 2024.

CEO Michael Kavanagh revealed that some of this profit growth comes from one-offs. He explains:

As a result of the increased first half revenue, the business expects to deliver profit before tax (PBT) of $10.9 million for the half. The expected PBT result includes a gain of approximately $1.3 million (compared to a $0.4 million loss in H1 FY24) due to the AUD exchange rate moving from 0.66 on 30 June 2024 to 0.62 on 31 December 2024. This movement created an unrealised FX gain on US dollar-denominated assets, partially offset by the group's hedging activities.

Outlook

Kavanagh believes that Nanosonics' first half performance means that it is on track to "achieve revenue, gross margin and operating expenses in FY25 around the top of each of the ranges for those measures specified in Nanosonics' FY25 outlook statement."

This includes total revenue growth of 8% to 12%, a gross margin of 77% to 79%, and operating expense growth of 6% to 10%.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Nanosonics. The Motley Fool Australia has positions in and has recommended Nanosonics. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

Starpharma: FY26 earnings reveal strong revenue growth and improved loss

Starpharma posted a sharp rise in FY26 revenue and narrowed its loss, with new funds extending its cash runway into…

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

Could this ASX biotech really jump more than 500%?

This company is in the ramp up phase.

Read more »

Happy, tablet or doctor in a laboratory with research results or positive feedback after medical data analysis. Smile, vaccine or healthcare worker reading or working on futuristic science innovation.
Earnings Results

Neuren Pharmaceuticals reports lower profit but launches first dividend

The pharmaceuticals company is returning funds to shareholders with its first ever dividend.

Read more »

A scientist examining test results.
Healthcare Shares

PolyNovo FY26 earnings: Revenue jumps, profit steady

PolyNovo posted double-digit revenue growth and positive profit for FY26, as manufacturing expansion and global reach supported its medtech ambitions.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Broker Notes

Bell Potter says this ASX biotech could nearly double in value

The US market is starting to open up for this company.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Integral Diagnostics posts profit and dividend growth in FY26

Integral Diagnostics FY26 earnings show revenue and profit growth, higher dividend, and a positive outlook for investors.

Read more »

A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.
Broker Notes

This ASX small-cap healthcare stock is tipped to double in value

This company has a good base to build on.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Neuren share price in focus after DAYBU wins EU approval for Rett syndrome

Neuren shares are on watch after DAYBU (trofinetide) won European approval, unlocking commercial milestones and revenue opportunities.

Read more »